Scinai Immunotherapeutics (NASDAQ: SCNI) announced execution of a Second Amendment to its Binding Option Agreement for the acquisition of PinCell S.r.l. and submission of a revised application under the European Funds for the Modern Economy SMART Path program. The updated application seeks EUR12 million in non-dilutive, non-repayable funding to support a EUR15 million integrated R&D program for PC111, a fully human monoclonal antibody targeting soluble Fas Ligand for the treatment of pemphigus vulgaris and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis, representing 80% co-financing. The amendment extends the option condition deadline to Aug. 31, 2026, and the exercise period to Sept. 30, 2026, aligning with the anticipated three- to four-month grant review timeline as the Company advances PC111 toward early clinical development and human proof of concept.

To view the full press release, visit https://ibn.fm/NmtDv

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biopharmaceutical company operating a contract development and manufacturing organization (CDMO) alongside a focused immunology R&D pipeline.

The Company's wholly owned CDMO unit provides fee-for-service development and manufacturing solutions to biotech and pharmaceutical companies across early-stage biologics and small-molecule programs. In parallel, Scinai is advancing a focused immunology pipeline, including PC111 and next-generation NanoAb-based programs, and is pursuing strategic partnerships, co-development agreements and regional licensing opportunities.

NOTE TO INVESTORS:â?¯The latest news and updates relating to SCNI are available in the company's newsroom atâ?¯https://ibn.fm/SCNI

About MissionIR

MissionIR ("MIR") is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
Editor@MissionIR.com

MissionIR is powered by IBN

COMTEX_474524538/2557/2026-03-02T13:05:35